Novel Nanoparticle Formulation Fights SCC

Chicago - A novel nanoparticle formulation of paclitaxel (ABI-007) administered intra-arterially has been shown to be well tolerated and very active against squamous carcinomas of the head and neck, uterus, and anal canal, Bruno Damascelli, M.D., said at the 39th annual meeting of the American Society of Clinical Oncology.

Related Videos
Related Content

The Connection Between COVID Lung Lesions and Skin Lesions

April 1st 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

FDA Panel Questions Isotretinoin iPLEDGE REMS

March 31st 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Photoprotection Can Improve Acne Outcomes

March 31st 2023

What's Trending in Skin Care: March 2023

March 31st 2023

The Connection Between COVID Lung Lesions and Skin Lesions

April 1st 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

FDA Panel Questions Isotretinoin iPLEDGE REMS

March 31st 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Photoprotection Can Improve Acne Outcomes

March 31st 2023

What's Trending in Skin Care: March 2023

March 31st 2023

The Connection Between COVID Lung Lesions and Skin Lesions

April 1st 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

FDA Panel Questions Isotretinoin iPLEDGE REMS

March 31st 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Photoprotection Can Improve Acne Outcomes

March 31st 2023

What's Trending in Skin Care: March 2023

March 31st 2023
© 2023 MJH Life Sciences

All rights reserved.